CL2017002405A1 - Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr. - Google Patents
Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr.Info
- Publication number
- CL2017002405A1 CL2017002405A1 CL2017002405A CL2017002405A CL2017002405A1 CL 2017002405 A1 CL2017002405 A1 CL 2017002405A1 CL 2017002405 A CL2017002405 A CL 2017002405A CL 2017002405 A CL2017002405 A CL 2017002405A CL 2017002405 A1 CL2017002405 A1 CL 2017002405A1
- Authority
- CL
- Chile
- Prior art keywords
- fxr
- diseases
- treatment
- pharmaceutical composition
- disorders related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>COMPUESTOS BICÍCLICOS FUSIONADOS; COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES O DESÓRDENES RELACIONADOS CON EL FXR TAL COMO HIPERLIPIDEMIA, HIPERCOLESTEROLEMIA, ATEROSCLEROSIS, DIABETES TIPO II Y OBESIDAD.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562138725P | 2015-03-26 | 2015-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002405A1 true CL2017002405A1 (es) | 2018-04-27 |
Family
ID=56072361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002405A CL2017002405A1 (es) | 2015-03-26 | 2017-09-25 | Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr. |
Country Status (16)
Country | Link |
---|---|
US (4) | US10421759B2 (es) |
EP (2) | EP3715348A1 (es) |
JP (1) | JP6843061B2 (es) |
KR (1) | KR20180003545A (es) |
CN (1) | CN107912042A (es) |
AU (2) | AU2016238523A1 (es) |
BR (1) | BR112017020374A2 (es) |
CA (1) | CA2980394A1 (es) |
CL (1) | CL2017002405A1 (es) |
CO (1) | CO2017010621A2 (es) |
HK (1) | HK1249756A1 (es) |
IL (1) | IL254572A0 (es) |
MX (1) | MX370897B (es) |
RU (2) | RU2017137366A (es) |
SG (2) | SG10201908881PA (es) |
WO (1) | WO2016151403A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201908881PA (en) * | 2015-03-26 | 2019-11-28 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
AU2017270221A1 (en) * | 2016-05-25 | 2018-12-20 | Akarna Therapeutics, Ltd. | Combination therapies with farnesoid X receptor (FXR) modulators |
RU2018145721A (ru) * | 2016-05-25 | 2020-06-25 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболеваний |
RU2019144064A (ru) * | 2017-06-02 | 2021-07-13 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения |
CN108264474B (zh) * | 2018-02-09 | 2019-10-25 | 浙江师范大学 | 一种色胺及其衍生物的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
US8466143B2 (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
CN101010078A (zh) | 2004-08-10 | 2007-08-01 | 埃克塞里艾克西斯公司 | 作为药物的杂环化合物 |
WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
EP1963331A1 (en) * | 2005-12-15 | 2008-09-03 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
US20090137554A1 (en) * | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
US20090131409A1 (en) | 2007-10-22 | 2009-05-21 | Wyeth | 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
EP2334681A1 (en) * | 2008-09-26 | 2011-06-22 | Wyeth LLC | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
WO2016081918A1 (en) * | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
RU2741387C2 (ru) * | 2014-12-22 | 2021-01-25 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
SG10201908881PA (en) * | 2015-03-26 | 2019-11-28 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
-
2016
- 2016-03-25 SG SG10201908881P patent/SG10201908881PA/en unknown
- 2016-03-25 CA CA2980394A patent/CA2980394A1/en not_active Abandoned
- 2016-03-25 CN CN201680029952.3A patent/CN107912042A/zh active Pending
- 2016-03-25 WO PCT/IB2016/000606 patent/WO2016151403A1/en active Application Filing
- 2016-03-25 MX MX2017012342A patent/MX370897B/es active IP Right Grant
- 2016-03-25 EP EP20158977.7A patent/EP3715348A1/en not_active Withdrawn
- 2016-03-25 BR BR112017020374A patent/BR112017020374A2/pt not_active IP Right Cessation
- 2016-03-25 KR KR1020177030777A patent/KR20180003545A/ko not_active Application Discontinuation
- 2016-03-25 RU RU2017137366A patent/RU2017137366A/ru unknown
- 2016-03-25 RU RU2021107054A patent/RU2021107054A/ru unknown
- 2016-03-25 SG SG11201707610PA patent/SG11201707610PA/en unknown
- 2016-03-25 EP EP16724699.0A patent/EP3274350A1/en not_active Withdrawn
- 2016-03-25 AU AU2016238523A patent/AU2016238523A1/en not_active Abandoned
- 2016-03-25 JP JP2017550113A patent/JP6843061B2/ja active Active
-
2017
- 2017-09-18 IL IL254572A patent/IL254572A0/en unknown
- 2017-09-25 CL CL2017002405A patent/CL2017002405A1/es unknown
- 2017-09-25 US US15/714,013 patent/US10421759B2/en active Active
- 2017-10-18 CO CONC2017/0010621A patent/CO2017010621A2/es unknown
-
2018
- 2018-07-12 HK HK18109050.8A patent/HK1249756A1/zh unknown
-
2019
- 2019-09-19 US US16/575,965 patent/US20200079782A1/en not_active Abandoned
-
2020
- 2020-10-12 AU AU2020256301A patent/AU2020256301A1/en not_active Abandoned
- 2020-11-17 US US17/099,864 patent/US20210214362A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,138 patent/US20230002394A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200079782A1 (en) | 2020-03-12 |
CO2017010621A2 (es) | 2018-01-31 |
US20210214362A1 (en) | 2021-07-15 |
SG10201908881PA (en) | 2019-11-28 |
US20180118752A1 (en) | 2018-05-03 |
US20230002394A1 (en) | 2023-01-05 |
EP3274350A1 (en) | 2018-01-31 |
BR112017020374A2 (pt) | 2018-06-05 |
KR20180003545A (ko) | 2018-01-09 |
MX2017012342A (es) | 2018-06-11 |
HK1249756A1 (zh) | 2018-11-09 |
AU2020256301A1 (en) | 2020-11-05 |
JP2018510876A (ja) | 2018-04-19 |
WO2016151403A1 (en) | 2016-09-29 |
CN107912042A (zh) | 2018-04-13 |
MX370897B (es) | 2020-01-09 |
RU2017137366A (ru) | 2019-04-26 |
RU2017137366A3 (es) | 2019-07-17 |
EP3715348A1 (en) | 2020-09-30 |
SG11201707610PA (en) | 2017-10-30 |
AU2016238523A1 (en) | 2017-11-09 |
IL254572A0 (en) | 2017-11-30 |
JP6843061B2 (ja) | 2021-03-17 |
RU2021107054A (ru) | 2021-03-31 |
US10421759B2 (en) | 2019-09-24 |
CA2980394A1 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
CL2017002405A1 (es) | Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr. | |
CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2016002751A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CL2016001889A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1. | |
CL2015003315A1 (es) | Inhibidores de acc y usos de los mismos | |
CL2015002738A1 (es) | Xantinas sustituidas y métodos de uso de las mismas. | |
CL2014002100A1 (es) | Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal. | |
CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
CL2015000094A1 (es) | Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide. | |
CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
CL2017000372A1 (es) | Composiciones novedosas, usos y métodos para hacerlas. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2014003572A1 (es) | Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis. |